Improving outcomes for patients with aggressive brain tumors is the focus of the latest U-M faculty member to be named a Taubman Emerging Scholar.
Daniel R. Wahl, MD, PhD, is an assistant professor in the department of Radiation Oncology.
Dr. Wahl and his research team believe that targeting metabolic abnormalities may be the key to overcoming glioblastoma (GBM) treatment resistance.
He will receive an award of $200,000 over five years, to be used toward laboratory research, through a gift to the institute from philanthropist William Parfet.
Dr. Wahl is developing new metabolic techniques to measure the activity of key metabolic pathways in GBM tumor patients. He is also developing clinical trials to combine standard GBM therapies with drugs that inhibit the metabolic pathways that cause treatment resistance.
The Taubman Emerging Scholars Program was established in 2011 to support early-career clinician-scientists on the University of Michigan Medical School faculty, as they establish their research programs and develop the credentials to qualify for traditional government and foundation grants. To date, 33 of these talented young physicians have received Emerging Scholar awards.
